Analysts Set Perspective Therapeutics, Inc. (NYSE:CATX) Target Price at $12.63

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have earned an average recommendation of "Buy" from the ten research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $12.63.

Several analysts recently issued reports on the company. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Perspective Therapeutics in a research note on Monday, March 31st. Truist Financial cut their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th.

Insider Activity

In related news, CEO Johan M. Spoor bought 22,026 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. The trade was a 58.96% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Robert F. Williamson III bought 22,192 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the acquisition, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. The trade was a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 115,696 shares of company stock worth $256,344. 3.72% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Y Intercept Hong Kong Ltd purchased a new position in Perspective Therapeutics in the fourth quarter valued at about $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter worth about $34,000. National Bank of Canada FI lifted its position in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth about $51,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Trading Up 0.3%

Shares of NYSE CATX traded up $0.01 during mid-day trading on Wednesday, hitting $3.46. The company had a trading volume of 1,013,275 shares, compared to its average volume of 1,085,781. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $16.55. The firm's 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $2.84.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.